Short answer
SI-BONE, Inc. (SIBN) filed its Q3 2026 10-Q quarterly report on Nov 3, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $56M (up 14.5% year over year) with net income of −$4M.
Q3 2026 key financials · XBRL
- Revenue
- $56M
- +14.5% YoY · −0.5% QoQ
- Net income
- −$4M
- +20.7% YoY · +11.4% QoQ
- Operating margin
- -7.8%
- Gross margin
- 79.3%
- EPS (diluted)
- −$0.08
- +20.0% YoY · +11.1% QoQ
Source: XBRL data from the SI-BONE, Inc. (SIBN) Q3 2026 10-Q on SEC EDGAR. USD.
SI-BONE, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $55.7M, up 14.5% YoY from $48.7M, driven by 19.5% procedure-volume growth
- Gross margin 79.3% vs 79.8% YoY, reflecting site-of-care and procedure-mix changes
- U.S. revenue $52.8M, up 13.9%; international revenue $2.9M, up 27.0%
- Operating cash flow $4.4M vs $(2.4)M YoY; investing outflow $13.1M, including $9.0M equipment purchases
- Cash and marketable securities $146.3M vs $147.8M at December 31, 2025; funding expected for next 12 months, with downturn and capital-market risks
Risk Factors
- New operational risk: tube packaging failure affected approximately 3,900 iFuse TORQ implants, including 98 voluntarily recalled units
- Regulatory risk: FDA Class II recall reporting followed potentially compromised sterility in iFuse TORQ implants
- Supply-chain risk: titanium availability and costs exposed to Russia-Ukraine disruptions and potential tariffs
- Product-liability risk: nonsterile packaging could increase infection risk and require revision surgery
- Manufacturing risk: limited-source components and contract sterilization constraints could disrupt product availability
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other SI-BONE, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.